PHAR Stock Analysis: Why Pharming Group NV Scored 23% in Stock Value Finder

Pharming Group NV (PHAR): A Detailed StockValueFinder Educational Review

Overview of Pharming Group NV (PHAR)

Pharming Group NV (PHAR) is a biotechnology company operating in the healthcare sector. Biotechnology firms typically focus on developing innovative therapies, often targeting rare or complex diseases where treatment options are limited. These companies invest heavily in research and development (R&D) to bring new drugs to market, which can lead to high growth potential but also comes with significant financial and operational risks.

This article is an educational review from StockValueFinder.com, designed to help investors understand how to evaluate stocks using specific financial metrics. We will examine Pharming Group NV through the lens of StockValueFinder’s quantitative screening system, which assesses companies based on earnings consistency, capital efficiency, financial safety, valuation discipline, and price trend. The goal is to provide a clear, number-driven analysis so readers can learn how to apply these concepts to other stocks.

Pharming Group NV currently holds a StockValueFinder score of 23%, resulting in an "AVOID" rating. This score reflects the company’s performance across several key financial tests, which we will explore in detail. The recent stock price is $11.20, and the analysis is based solely on the supplied metrics—no additional financial data, analyst estimates, or future projections have been incorporated.

Why the StockValueFinder Score Matters

The StockValueFinder score is a composite measure that evaluates a company’s financial health and valuation discipline. It ranges from 0% to 100%, with higher scores indicating stronger performance across the tested metrics. The score is not a prediction of future stock performance but rather a tool to help investors identify companies that meet specific financial criteria.

A score of 23% places Pharming Group NV in the "AVOID" category. This does not mean the stock will necessarily decline or that the company is poorly managed—it simply indicates that the company did not pass several of the system’s financial tests. For context, StockValueFinder generally considers scores below 50% as less attractive for investors seeking financially strong and reasonably valued companies.

The score is derived from the following metrics

– Earnings Per Share (EPS) strength – Return on Invested Capital (ROIC) – Interest coverage – Debt payback – Price-to-Earnings (P/E) ratio – Moving average trend

Each of these metrics provides insight into a different aspect of the company’s financial profile. By examining them individually, investors can better understand the strengths and weaknesses of Pharming Group NV.

EPS Strength and Consistency

What Is EPS and Why Does It Matter?

Earnings Per Share (EPS) measures a company’s profitability on a per-share basis. It is calculated by dividing net income by the number of outstanding shares. EPS is a critical metric because it reflects how much money a company earns for each share of its stock. Consistent or growing EPS over time is often a sign of a stable and well-managed business.

StockValueFinder evaluates EPS strength by examining the company’s earnings history for consistency and growth. Companies that pass this test typically demonstrate steady or improving earnings over multiple quarters or years. In contrast, companies with volatile or declining EPS may fail this test, as inconsistent earnings can signal operational challenges or market risks.

Pharming Group NV’s EPS Performance

For Pharming Group NV, the StockValueFinder system recorded a result of "Did not pass" for the EPS test. This means the company’s earnings history did not meet the system’s criteria for consistency or growth. While the exact EPS values are not supplied, the failure suggests that Pharming’s earnings may have been erratic, declining, or insufficient to meet the screening threshold.

Why EPS Consistency Matters: An Example

To illustrate why EPS consistency is important, consider two hypothetical companies

– **Company A** has reported EPS of $1.00, $1.10, $1.20, and $1.30 over the last four quarters. This steady growth suggests the company is expanding its profitability in a predictable manner. – **Company B** has reported EPS of $1.00, $0.50, $1.50, and $0.20 over the same period. The volatility in Company B’s earnings could indicate operational challenges, market competition, or other risks that make it harder to forecast future performance.

Investors often prefer companies with stable or growing EPS because they provide greater confidence in the company’s ability to generate profits over time. Pharming Group NV’s failure to pass the EPS test suggests that its earnings may not meet this standard of consistency.

ROIC and Capital Efficiency

What Is ROIC and Why Does It Matter?

Return on Invested Capital (ROIC) measures how effectively a company uses its capital to generate profits. It is calculated by dividing net operating profit after taxes (NOPAT) by the total capital invested in the business (including debt and equity). ROIC is a key indicator of capital efficiency—companies with high ROIC are generally better at allocating resources to generate returns for shareholders.

StockValueFinder typically looks for ROIC of 10% or higher, as this suggests the company is generating strong returns relative to its capital base. Companies with ROIC below 10% may struggle to create value for shareholders, especially if their returns are consistently low.

Pharming Group NV’s ROIC

Pharming Group NV’s ROIC is 0.73%. This is significantly below the 10% threshold that StockValueFinder considers attractive. The low ROIC indicates that the company is not generating substantial returns on the capital it has invested in its operations.

Why ROIC Matters: An Example

To understand the importance of ROIC, consider two companies

– **Company X** has an ROIC of 15%. This means that for every $100 of capital invested, the company generates $15 in profit after taxes. This is a strong return and suggests the company is using its capital efficiently. – **Company Y** has an ROIC of 4%. For every $100 of capital invested, it generates only $4 in profit. This lower return may indicate inefficiencies, competitive pressures, or other challenges that limit profitability.

Pharming Group NV’s ROIC of 0.73% is far below even Company Y’s 4%, suggesting that the company is struggling to generate meaningful returns on its invested capital. This is a key reason why the stock failed the ROIC test.

Interest Coverage and Financial Safety

What Is Interest Coverage and Why Does It Matter?

Interest coverage measures a company’s ability to pay the interest on its debt. It is calculated by dividing earnings before interest and taxes (EBIT) by the company’s interest expenses. A higher interest coverage ratio indicates that the company has a stronger ability to meet its debt obligations, while a lower ratio suggests financial strain.

StockValueFinder generally prefers an interest coverage ratio of 6 or higher. This threshold provides a margin of safety, ensuring that the company can comfortably cover its interest payments even if earnings decline temporarily.

Pharming Group NV’s Interest Coverage

The StockValueFinder system recorded a result of "Did not pass" for Pharming Group NV’s interest coverage test. While the exact interest coverage ratio is not supplied, the failure suggests that the company’s ability to cover its interest expenses may be weak. This could indicate higher financial risk, particularly if the company’s earnings are volatile or declining.

Why Interest Coverage Matters: An Example

Consider two companies

– **Company M** has an interest coverage ratio of 8. This means its earnings are 8 times its interest expenses, providing a strong cushion to cover debt payments. – **Company N** has an interest coverage ratio of 2. Its earnings are only twice its interest expenses, leaving little room for error if earnings decline.

Pharming Group NV’s failure to pass the interest coverage test suggests that its ratio may be closer to Company N’s 2 than to Company M’s 8. This raises concerns about the company’s financial flexibility and ability to manage its debt obligations.

Debt Payback and Balance Sheet Discipline

What Is Debt Payback and Why Does It Matter?

Debt payback measures how long it would take a company to pay off its total debt using its current operating cash flow. It is calculated by dividing total debt by annual operating cash flow. A shorter debt payback period indicates a stronger balance sheet and lower financial risk, as the company can quickly reduce its debt burden.

StockValueFinder typically prefers a debt payback period of 3 years or less. Companies with longer debt payback periods may face higher financial risk, especially if their cash flow is inconsistent or declining.

Pharming Group NV’s Debt Payback

Pharming Group NV’s debt payback period is 1.72 years. This is well below the 3-year threshold, indicating that the company could pay off its debt relatively quickly using its operating cash flow. This is a positive sign for balance sheet discipline and financial stability.

Why Debt Payback Matters: An Example

Consider two companies

– **Company P** has a debt payback period of 1.5 years. This means it could eliminate its debt in just 18 months using its current cash flow, indicating a strong financial position. – **Company Q** has a debt payback period of 7 years. It would take much longer to pay off its debt, which could strain its finances if cash flow declines or interest rates rise.

Pharming Group NV’s debt payback period of 1.72 years is closer to Company P’s 1.5 years, suggesting that the company has a manageable debt load relative to its cash flow. This is the only test that Pharming Group NV passed in the StockValueFinder system.

P/E Ratio and Valuation Discipline

What Is the P/E Ratio and Why Does It Matter?

The Price-to-Earnings (P/E) ratio measures a company’s stock price relative to its earnings per share. It is calculated by dividing the stock price by the EPS. The P/E ratio is a key valuation metric—it helps investors assess whether a stock is overvalued, undervalued, or fairly valued relative to its earnings.

StockValueFinder generally prefers a P/E ratio of 15 or lower for valuation discipline. A lower P/E ratio suggests that the stock may be more attractively priced relative to its earnings, while a higher P/E ratio may indicate that the stock is expensive or that investors have high growth expectations.

Pharming Group NV’s P/E Ratio

Pharming Group NV’s P/E ratio is 86.15. This is significantly above the 15 threshold that StockValueFinder considers attractive. The high P/E ratio suggests that investors are paying a premium for the company’s earnings, which may reflect expectations for future growth or other factors.

Why the P/E Ratio Matters: An Example

Consider two companies

– **Company R** has a P/E ratio of 8. This means investors are paying $8 for every $1 of earnings, which may indicate an undervalued or stable business. – **Company S** has a P/E ratio of 40. Investors are paying $40 for every $1 of earnings, which may reflect high growth expectations or an overvalued stock.

Pharming Group NV’s P/E ratio of 86.15 is more than double Company S’s 40, suggesting that the stock is trading at a substantial premium to its current earnings. This is a key reason why the stock failed the P/E valuation test.

Moving Average Trend and Entry Timing

What Is the Moving Average Trend and Why Does It Matter?

The moving average trend is a technical indicator that helps investors assess the stock’s price momentum. It is calculated by comparing the stock’s current price to its average price over a specific period (e.g., 50-day or 200-day moving average). A strong trend suggests that the stock is gaining momentum, while a weak trend may indicate stagnation or decline.

StockValueFinder uses the moving average trend as a timing tool, not as a predictor of future performance. A strong trend does not guarantee that the stock will continue to rise, but it can provide context for evaluating entry points.

Pharming Group NV’s Moving Average Trend

Pharming Group NV’s moving average signal is "WEAK TREND." This suggests that the stock’s price momentum is not strong, which may make it less attractive for investors seeking stocks with upward price momentum. The entry signal is listed as "N/A," indicating that the system did not identify a favorable entry point based on the current trend.

Why the Moving Average Trend Matters: An Example

Consider two stocks

– **Stock T** has a strong moving average trend, with its current price trading above both its 50-day and 200-day moving averages. This suggests positive momentum and may appeal to investors looking for stocks with upward price trends. – **Stock U** has a weak moving average trend, with its current price trading below its moving averages. This may indicate stagnation or decline, making it less attractive for momentum-focused investors.

Pharming Group NV’s weak trend suggests that its price momentum is not strong, which may deter investors who prioritize technical strength in their stock selection.

Overall Financial Strengths and Weaknesses

Pharming Group NV’s financial profile presents a mixed picture, with both strengths and weaknesses:

Strengths

1. **Debt Payback**: The company’s debt payback period of 1.72 years is a positive sign, indicating that it can quickly reduce its debt burden using its operating cash flow. This suggests a relatively strong balance sheet and lower financial risk compared to companies with longer debt payback periods.

Weaknesses

1. **EPS Consistency**: The company failed the EPS test, suggesting that its earnings may be volatile or inconsistent. This raises concerns about the stability of its profitability. 2. **ROIC**: With an ROIC of 0.73%, Pharming Group NV is not generating strong returns on its invested capital. This indicates inefficiencies in how the company allocates its resources. 3. **Interest Coverage**: The company failed the interest coverage test, suggesting that its ability to cover interest expenses may be weak. This could indicate higher financial risk. 4. **P/E Ratio**: The P/E ratio of 86.15 is significantly above the threshold that StockValueFinder considers attractive. This suggests that the stock may be overvalued relative to its current earnings. 5. **Moving Average Trend**: The weak trend signal indicates that the stock’s price momentum is not strong, which may make it less appealing to investors seeking upward price trends.

Risks and Limitations

Investing in biotechnology companies like Pharming Group NV carries unique risks and limitations that investors should consider:

1. **R&D Risk**: Biotechnology companies often rely on successful drug development to drive growth. If a company’s R&D efforts fail to produce viable therapies, its financial performance could suffer. 2. **Regulatory Risk**: The biotechnology industry is heavily regulated. Delays or rejections from regulatory agencies (e.g., the FDA) can significantly impact a company’s ability to bring products to market. 3. **Market Risk**: Biotech stocks can be highly volatile, with prices influenced by clinical trial results, regulatory news, and market sentiment. This volatility can lead to significant price swings. 4. **Financial Risk**: Companies with low ROIC, weak interest coverage, or high P/E ratios may face challenges in generating consistent returns for shareholders. Pharming Group NV’s financial metrics reflect some of these risks. 5. **Limited Data**: This analysis is based solely on the supplied metrics. Additional financial data, such as revenue growth, cash flow trends, or product pipeline details, could provide further context but are not included here.

Educational Conclusion

This educational review of Pharming Group NV (PHAR) demonstrates how investors can use quantitative metrics to evaluate a company’s financial health and valuation. By examining EPS consistency, ROIC, interest coverage, debt payback, P/E ratio, and moving average trend, investors can gain a clearer understanding of a stock’s strengths and weaknesses.

Pharming Group NV’s StockValueFinder score of 23% and "AVOID" rating reflect its performance across these metrics. The company passed only one test (debt payback) and failed the remaining five, indicating areas of concern such as low capital efficiency, weak interest coverage, and a high P/E ratio. While the company’s debt payback period is a positive sign, the overall financial profile suggests that it may not meet the criteria for investors seeking financially strong and reasonably valued stocks.

This analysis is not a recommendation to buy or sell Pharming Group NV. Instead, it serves as an educational example of how to apply financial metrics to stock research. Investors should conduct their own due diligence, consider their risk tolerance, and consult with a financial advisor before making investment decisions.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.

---

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings